{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-034204","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.548340+00:00","generated_at":"2026-06-04T21:27:22.116068+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immuneering doses first patient in Phase 2a of IMM-1-104; Phase 1 data shows safety and biomarker activity","bullets":["First patient dosed in Phase 2a of IMM-1-104; ~150 patients planned across 5 arms (monotherapy and combination).","Phase 1 (N=41): no grade 4 TRAEs; only one grade 3 (reversible rash); most common grade 1/2: diarrhea 19.5%, nausea 19.5%.","At 320mg, pERK inhibition ≥90% for 2.7h; 100% of evaluable patients (N=22) showed no new RAS or MAPK pathway mutations by ctDNA.","53% of patients had ≥1 target lesion regression at 240/320mg; best individual regression -35.7% at 320mg in second-line.","Thomas J. Schall, Ph.D. appointed to Board of Directors as Class I Director effective March 11, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-034204","json":"https://secwatch.observer/filing/0001104659-24-034204.json","markdown":"https://secwatch.observer/filing/0001104659-24-034204.md","text":"https://secwatch.observer/filing/0001104659-24-034204.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000110465924034204/0001104659-24-034204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000110465924034204/tm248799d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:27:22.116068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cd6f363ca","claim":"Thomas J. Schall, Ph.D. was appointed as Director at Immuneering Corp.","evidence_excerpt":"On March 11, 2024, the Board of Directors of Immuneering Corporation (“we,” “our” and “us”) appointed Thomas J. Schall, Ph.D. to serve as a member of our Board of Directors as a Class I Director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1790340/000110465924034204/0001104659-24-034204-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}